$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr

$csbr Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-K Financial Statement

#000162828023025464 Filed on July 24, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2023
Revenue	$12.56M	$13.07M	$53.87M
YoY Change	-8.61%	1.51%	9.69%
Cost Of Revenue	$7.684M	$7.338M	$29.53M
YoY Change	8.96%	17.96%	24.97%
Gross Profit	$4.877M	$5.733M	$24.34M
YoY Change	-27.13%	-13.87%	-4.47%
Gross Profit Margin	38.83%	43.86%	45.18%
Selling, General & Admin	$4.636M	$4.595M	$17.24M
YoY Change	13.35%	5.0%	11.27%
% of Gross Profit	95.06%	80.15%	70.84%
Research & Development	$2.793M	$2.852M	$11.55M
YoY Change	-3.26%	10.07%	23.16%
% of Gross Profit	57.27%	49.75%	47.44%
Depreciation & Amortization	$445.0K	$583.0K	$2.246M
YoY Change	-10.82%	2.64%	49.73%
% of Gross Profit	9.12%	10.17%	9.23%
Operating Expenses	$7.429M	$7.447M	$28.79M
YoY Change	6.48%	6.89%	15.75%
Operating Profit	-$2.552M	-$1.714M	-$4.449M
YoY Change	798.59%	451.13%	-832.95%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$14.00K	-$20.00K	-$11.00K
YoY Change	-177.78%	-42.86%	-54.17%
Pretax Income	-$2.538M	-$2.541M	-$5.267M
YoY Change	740.4%	634.39%	-1003.43%
Income Tax	$28.00K	$20.00K	$68.00K
% Of Pretax Income
Net Earnings	-$2.600M	-$2.561M	-$5.335M
YoY Change	715.05%	644.48%	-1073.54%
Net Earnings / Revenue	-20.7%	-19.59%	-9.9%
Basic Earnings Per Share	-$0.19		-$0.39
Diluted Earnings Per Share	-$0.19	-$0.19	-$0.39
COMMON SHARES
Basic Shares Outstanding	13.46M shares		13.54M shares
Diluted Shares Outstanding	13.51M shares		13.54M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.869M	$10.12M	$10.12M
YoY Change	-39.58%	12.33%	12.33%
Cash & Equivalents	$4.900M	$10.12M	$10.12M
Short-Term Investments
Other Short-Term Assets	$1.105M	$1.328M	$1.328M
YoY Change	15.34%	16.08%	16.08%
Inventory
Prepaid Expenses
Receivables	$8.948M	$8.011M	$8.011M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$14.92M	$19.46M	$19.46M
YoY Change	-18.77%	-1.05%	-1.05%
LONG-TERM ASSETS
Property, Plant & Equipment	$14.47M	$14.50M	$14.50M
YoY Change	87.91%	-5.6%	-5.6%
Goodwill	$335.0K	$335.0K
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$184.0K	$15.00K	$15.00K
YoY Change	1126.67%	0.0%	0.0%
Total Long-Term Assets	$14.98M	$14.85M	$14.85M
YoY Change	-6.46%	-5.47%	-5.47%
TOTAL ASSETS
Total Short-Term Assets	$14.92M	$19.46M	$19.46M
Total Long-Term Assets	$14.98M	$14.85M	$14.85M
Total Assets	$29.91M	$34.31M	$34.31M
YoY Change	-13.04%	-3.02%	-3.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.759M	$5.334M	$5.334M
YoY Change	127.0%	85.98%	85.98%
Accrued Expenses	$2.091M	$3.478M	$3.478M
YoY Change	6.85%	44.08%	0.29%
Deferred Revenue	$11.14M	$12.78M
YoY Change	2.36%	15.4%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$20.38M	$21.73M	$21.73M
YoY Change	22.64%	24.34%	24.34%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$514.0K	$7.942M	$7.942M
YoY Change	-22.12%	1931.2%	-9.78%
Total Long-Term Liabilities	$514.0K	$7.942M	$7.942M
YoY Change	-22.12%	1931.2%	-9.78%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.38M	$21.73M	$21.73M
Total Long-Term Liabilities	$514.0K	$7.942M	$7.942M
Total Liabilities	$28.00M	$29.68M	$29.68M
YoY Change	10.22%	12.91%	12.91%
SHAREHOLDERS EQUITY
Retained Earnings	-$79.90M	-$77.30M
YoY Change	10.51%	7.36%
Common Stock	$82.46M	$82.03M
YoY Change	1.45%	1.17%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.903M	$4.636M	$4.636M
YoY Change
Total Liabilities & Shareholders Equity	$29.91M	$34.31M	$34.31M
YoY Change	-13.04%	-3.02%	-3.02%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2023
OPERATING ACTIVITIES
Net Income	-$2.600M	-$2.561M	-$5.335M
YoY Change	715.05%	644.48%	-1073.54%
Depreciation, Depletion And Amortization	$445.0K	$583.0K	$2.246M
YoY Change	-10.82%	2.64%	49.73%
Cash From Operating Activities	-$4.000M	-$692.0K	$3.972M
YoY Change	1951.28%	-186.93%	-38.86%
INVESTING ACTIVITIES
Capital Expenditures	$668.0K	$760.0K	$2.872M
YoY Change	-11.41%	-250.2%	20.47%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$668.0K	-$760.0K	-$2.872M
YoY Change	-11.41%	50.2%	20.47%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		-$75.00K	$11.00K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$590.0K	-75.00K	11.00K
YoY Change		-568.75%	-94.69%
NET CHANGE
Cash From Operating Activities	-$4.000M	-692.0K	3.972M
Cash From Investing Activities	-$668.0K	-760.0K	-2.872M
Cash From Financing Activities	-$590.0K	-75.00K	11.00K
Net Change In Cash	-$5.249M	-1.527M	1.111M
YoY Change	453.11%	-599.02%	-74.28%
FREE CASH FLOW
Cash From Operating Activities	-$4.000M	-$692.0K	$3.972M
Capital Expenditures	$668.0K	$760.0K	$2.872M
Free Cash Flow	-$4.668M	-$1.452M	$1.100M
YoY Change	391.89%	-211.52%	-73.26%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0000771856
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2023#ServiceMember
CY2022	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2023#ServiceMember
CY2023	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2023#ServiceMember
CY2022	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2023#ServiceMember
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--04-30
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Public Float EntityPublicFloat	28000000	usd
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13459539	shares
CY2023	dei	Auditor Firm AuditorFirmId	274
CY2023	dei	Auditor Name AuditorName	EisnerAmper LLP
CY2023	dei	Auditor Location AuditorLocation	Iselin, New Jersey
CY2023Q2	us-gaap	Cash Cash	10118000	usd
CY2022Q2	us-gaap	Cash Cash	9007000	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8011000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9513000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1328000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1144000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	19457000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	19664000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7318000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8230000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8230000	usd
CY2023Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	7186000	usd
CY2022Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	7134000	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	15000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	15000	usd
CY2023Q2	us-gaap	Goodwill Goodwill	335000	usd
CY2022Q2	us-gaap	Goodwill Goodwill	335000	usd
CY2023Q2	us-gaap	Assets Assets	34311000	usd
CY2022Q2	us-gaap	Assets Assets	35378000	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	5334000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2868000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2270000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2414000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1208000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1054000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1054000	usd
CY2023Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	145000	usd
CY2022Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	72000	usd
CY2023Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	12776000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	11071000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	21733000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	17479000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7391000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8412000	usd
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	551000	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	391000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	29675000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	26282000	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13558650	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13522441	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13544228	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13522441	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	14000	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	14000	usd
CY2023Q2	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	74000	usd
CY2022Q2	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	0	usd
CY2023Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	82013000	usd
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	81064000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-77317000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-71982000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	4636000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	9096000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	34311000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35378000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	53870000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	49109000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	29532000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	23632000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9374000	usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	807000	usd
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-11000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5267000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	583000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	68000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	35000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5335000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	548000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.39
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.39
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.04
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13541559	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13197170	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13541559	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14159799	shares
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	7428000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	912000	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	208000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	548000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	9096000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	864000	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	85000	usd
CY2023	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	14422	shares
CY2023	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	74000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5335000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	4636000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5335000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	864000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	912000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2246000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1627000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	4000	usd
CY2023	csbr	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	952000	usd
CY2022	csbr	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	786000	usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	807000	usd
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	195000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	292000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1308000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2818000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	184000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	187000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2465000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	974000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-145000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	183000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-907000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-631000	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1706000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	4815000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3972000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	6497000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2872000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2384000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2872000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2384000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	85000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	207000	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	74000	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	207000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1111000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4320000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9007000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4687000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10118000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9007000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	231000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	205000	usd
CY2023	csbr	Numberof Operating Subsidiaries NumberofOperatingSubsidiaries	3	subsidiary
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include, among other things, accounts receivable realization, revenue recognition, valuation allowance for deferred tax assets, recoverability of capitalized software development costs, and stock-based compensation and warrant assumptions. We base our estimates on historical experience, our observance of trends in particular areas and information or valuations and various other assumptions that we believe to be reasonable under the circumstances and which form the basis for making judgments about the carrying value of assets and liabilities that may not be readily apparent from other sources. Actual amounts could differ significantly from amounts previously estimated.</span></div>
CY2023Q2	us-gaap	Cash Cash	10100000	usd
CY2022Q2	us-gaap	Cash Cash	9000000.0	usd
CY2023Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5300000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-77300000	usd
CY2023Q2	csbr	Working Capital WorkingCapital	-2300000	usd
CY2023Q2	us-gaap	Cash Cash	10100000	usd
CY2022Q2	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	4106000	usd
CY2021Q2	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	3020000	usd
CY2023Q2	us-gaap	Accounts Receivable Gross AccountsReceivableGross	8836000	usd
CY2022Q2	us-gaap	Accounts Receivable Gross AccountsReceivableGross	10143000	usd
CY2021Q2	us-gaap	Accounts Receivable Gross AccountsReceivableGross	7324000	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	825000	usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	807000	usd
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	181000	usd
CY2023Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	181000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	68000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	35000	usd
CY2023Q2	csbr	Trade Accounts Receivable TradeAccountsReceivable	3843000	usd
CY2022Q2	csbr	Trade Accounts Receivable TradeAccountsReceivable	6037000	usd
CY2021Q2	csbr	Trade Accounts Receivable TradeAccountsReceivable	4304000	usd
CY2023Q2	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	4993000	usd
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	630000	usd
CY2021Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	338000	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8011000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9513000	usd
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6986000	usd
CY2023Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	12776000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	11071000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	15816000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12711000	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8630000	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5577000	usd
CY2023Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	7186000	usd
CY2022Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	7134000	usd
CY2023Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	2200000	usd
CY2022Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	1600000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2100000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1500000	usd
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	1000000	usd
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	713000	usd
CY2023Q2	us-gaap	Servicing Asset ServicingAsset	1900000	usd
CY2023	us-gaap	Hosting Arrangement Service Contract Implementation Cost Expense Amortization HostingArrangementServiceContractImplementationCostExpenseAmortization	630000	usd
CY2022	us-gaap	Hosting Arrangement Service Contract Implementation Cost Expense Amortization HostingArrangementServiceContractImplementationCostExpenseAmortization	317000	usd
CY2023Q2	us-gaap	Servicing Asset At Fair Value Amount ServicingAssetAtFairValueAmount	807000	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.029
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.039
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	53870000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	49109000	usd
CY2023	us-gaap	Royalty Expense RoyaltyExpense	212000	usd
CY2022	us-gaap	Royalty Expense RoyaltyExpense	401000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	864000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	912000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	864000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	912000	usd
CY2013Q4	csbr	Stock Options Award Shares To Purchase Common Stock StockOptionsAwardSharesToPurchaseCommonStock	16667	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.008
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.012
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.61
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.63
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.64
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.66
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.31
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.56
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1658239	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.51
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y10M24D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6131000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	186720	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.22
CY2023	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P9Y4M24D
CY2023	csbr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Aggregate Intrinsic Value Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted	0	usd
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	36209	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.21
CY2023	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Canceled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod	13874	shares
CY2023	csbr	Share Based Compensation Arrangements By Share Based Payment Award Options Canceled In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice	3.93
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	14625	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.94
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	4584	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	5.40
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1775667	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.80
CY2023	csbr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Grant In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm	P4Y7M6D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2683000	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1775667	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.80
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y7M6D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	2683000	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1438807	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.35
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y9M18D
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2681000	usd
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1653646	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.96
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y4M24D
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	11384000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	166052	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.44
CY2022	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P9Y3M18D
CY2022	csbr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Aggregate Intrinsic Value Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted	0	usd
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	108375	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.29
CY2022	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Canceled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod	11209	shares
CY2022	csbr	Share Based Compensation Arrangements By Share Based Payment Award Options Canceled In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice	4.71
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	36875	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.45
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	5000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	9.60
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1658239	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.51
CY2022	csbr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Grant In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm	P4Y10M24D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6131000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1658239	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.51
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y10M24D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	6131000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1354479	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.93
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y2M12D
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	5778000	usd
CY2023Q1	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	5000000	usd
CY2023	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	14000	shares
CY2023	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	5.11
CY2023	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	74000	usd
CY2023Q2	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	4900000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	15000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	53000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	68000	usd
CY2023	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0	usd
CY2023	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	15000	usd
CY2023	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	53000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	68000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	10000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	25000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	35000	usd
CY2022	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0	usd
CY2022	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	10000	usd
CY2022	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	25000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	35000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.002
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.013
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.022
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.033
CY2023	csbr	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.005
CY2022	csbr	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.473
CY2023	csbr	Effective Income Tax Rate Reconciliation Increase In Uncertain Tax Position EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition	0
CY2022	csbr	Effective Income Tax Rate Reconciliation Increase In Uncertain Tax Position EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.238
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.277
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.013
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.060
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	273000	usd
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	162000	usd
CY2023Q2	csbr	Deferred Tax Assets Tax Deferred Expense Right Of Use Asset Liability DeferredTaxAssetsTaxDeferredExpenseRightOfUseAssetLiability	403000	usd
CY2022Q2	csbr	Deferred Tax Assets Tax Deferred Expense Right Of Use Asset Liability DeferredTaxAssetsTaxDeferredExpenseRightOfUseAssetLiability	316000	usd
CY2023Q2	csbr	Deferred Tax Liability Deferred Expense Depreciation And Amortization DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization	297000	usd
CY2022Q2	csbr	Deferred Tax Liability Deferred Expense Depreciation And Amortization DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization	396000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4024000	usd
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3874000	usd
CY2023Q2	csbr	Deferred Tax Liabilities Capitalized Research And Development Costs DeferredTaxLiabilitiesCapitalizedResearchAndDevelopmentCosts	2597000	usd
CY2022Q2	csbr	Deferred Tax Liabilities Capitalized Research And Development Costs DeferredTaxLiabilitiesCapitalizedResearchAndDevelopmentCosts	0	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9756000	usd
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	11546000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	16756000	usd
CY2022Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	15502000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	16756000	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15502000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	16800000	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15500000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1300000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	200000	usd
CY2023Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	41300000	usd
CY2022Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	48000000	usd
CY2013Q2	csbr	Operating Loss Carryforwards Limitations On Use Amount OperatingLossCarryforwardsLimitationsOnUseAmount	12000000	usd
CY2023Q2	csbr	Operating Loss Carryforwards Limitations On Use Amount OperatingLossCarryforwardsLimitationsOnUseAmount	432000	usd
CY2022Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	181000	usd
CY2021Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	181000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2023Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	181000	usd
CY2022Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	181000	usd
CY2022Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	181000	usd
CY2023Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	181000	usd
CY2022Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	181000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5335000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	548000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13541559	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13197170	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.39
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5335000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	548000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5335000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	548000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13541559	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13197170	shares
CY2023	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	962629	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13541559	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14159799	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.39
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.04
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1775667	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1658239	shares
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	1900000	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	1900000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7318000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8230000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8230000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1208000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1054000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1054000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7391000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8412000	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y8M12D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0582
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2841000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2889000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2938000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2904000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2854000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	2390000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	16816000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	8217000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	8599000	usd

Files In Submission

Name	View Source	Status
0001628280-23-025464-index-headers.html	Edgar Link	pending
0001628280-23-025464-index.html	Edgar Link	pending
0001628280-23-025464.txt	Edgar Link	pending
0001628280-23-025464-xbrl.zip	Edgar Link	pending
csbr-20230430.htm	Edgar Link	pending
csbr-20230430.xsd	Edgar Link	pending
csbrex214302023.htm	Edgar Link	pending
csbrex2314302023.htm	Edgar Link	pending
csbrex3114302023.htm	Edgar Link	pending
csbrex3124302023.htm	Edgar Link	pending
csbrex3214302023.htm	Edgar Link	pending
csbrex414302023.htm	Edgar Link	pending
csbr-20230430_def.xml	Edgar Link	unprocessable
csbr-20230430_lab.xml	Edgar Link	unprocessable
csbr-20230430_pre.xml	Edgar Link	unprocessable
csbr-20230430_htm.xml	Edgar Link	completed
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
csbr-20230430_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr

2023 Q3 Form 10-K Financial Statement

#000162828023025464 Filed on July 24, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSBR CHAMPIONS ONCOLOGY, INC. Stock $csbr

2023 Q3 Form 10-K Financial Statement

#000162828023025464 Filed on July 24, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr